Cost-Analysis of Chronic Idiopathic Urticaria Disease.

Tatar, M; Senturk, A; Ergin, G; Tuna, E; Mat, C; Bulbul, Baskan E; Artuz, F; Gurer, M A; Atakan, N; Inaloz, S; Sezen, S; Keskinaslan, A; Saylan, M

Tatar, M; Senturk, A; Ergin, G; Tuna, E; Mat, C; Bulbul, Baskan E; Artuz, F; Gurer, M A; Atakan, N; Inaloz, S; Sezen, S; Keskinaslan, A; Saylan, M.

Afiliação

Tatar M; Hacettepe University, Ankara, Turkey.
Senturk A; Polar Polar Health Economics & Policy, Ankara, Turkey.
Ergin G; Polar Polar Health Economics & Policy, Ankara, Turkey.
Tuna E; Polar Polar Health Economics & Policy, Ankara, Turkey.
Mat C; Cerrahpasa Medical Faculty, Istanbul, Turkey.
Bulbul BE; Uludag Medical Faculty, Bursa, Turkey.
Artuz F; Ankara Numune research and Training Hosptial, Ankara, Turkey.
Gurer MA; Gazi University Medical Faculty, Ankara, Turkey.
Atakan N; Hacettepe University Faculty of Medicine, Ankara, Turkey.
Inaloz S; Gaziantep University Medical Faculty, Gaziantep, Turkey.
Sezen S; Novartis Pharma, Istanbul, Turkey.
Keskinaslan A; Novartis Pharma, Istanbul, Turkey.
Saylan M; Novartis Pharma, Istanbul, Turkey.

Value Health ; 17(7): A606, 2014 Nov.

Article em En | MEDLINE | ID: mdl-27202104

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google